Spruce Street Capital’s Cidara Therapeutics CDTX Stock Holding History

Spruce Street Capital’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-232,269	Closed	-$51.3M	–	30
2025 Q4	$51.3M	Buy	+232,269	New	+$37.5M	16.95%	1

Spruce Street Capital's CDTX Position: Q1 2026 in Review

Spruce Street Capital sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 232,269 shares — an estimated $51.3M sold.

Spruce Street Capital first reported a position in CDTX in Q4 2025 and held it in 1 quarter. The position peaked at $51.3M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Spruce Street Capital reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Spruce Street Capital sold 232,269 Cidara Therapeutics shares in Q1 2026, an estimated $51.3M.
Spruce Street Capital first reported a position in Cidara Therapeutics in Q4 2025 and held it in 1 quarter.
Spruce Street Capital's Cidara Therapeutics position peaked at $51.3M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Spruce Street Capital's 13F filing for Q1 2026, filed 14 May 2026.